FVIIa - Coagulation factor VIIa
Cat# AS00001
Size : 50µg
Brand : Agrisera
Product no: AS00 001
AS00 001 | Clonality: Polyclonal | Host: Rabbit | Reactivity: Human
- Product Info
-
Immunogen: Recombinant human Factor VIIa (NovoSeven ®, Novo Nordisk A/S Denmark) Host: Rabbit Clonality: Polyclonal Purity: Immunogen affinity purified IgG in PBS pH 7.4. Format: Lyophilized Quantity: 50 µg Reconstitution: For reconstitution add 50 µl of sterile water Storage: Store lyophilized/reconstituted at -20°C; once reconstituted make aliquots to avoid repeated freeze-thaw cycles. Please remember to spin the tubes briefly prior to opening them, to avoid any losses that might occur from material adhering to the cap or sides of the tube. Tested applications: Prothrombin assay with human plasma (PT), thrombin generation assay, inhibition assay with Factor VIIa with TF and a chromogenic substrate, inDirect ELISA (I-ELISA) Recommended dilution: 1 : 15 000 (I-ELISA), 14 µg/ml (IL) Expected | apparent MW: 52 kDa (this is MW of Factor VIIa)
- Reactivity
-
Confirmed reactivity: Human Predicted reactivity: Primates Not reactive in: No confirmed exceptions from predicted reactivity are currently known - Additional Information
-
Additional information: No significant difference in binding to Factor VII and Factor VIIa.
Antibody is purified to total IgG fraction, followed by purification on specific FVIIa column.Additional information (application): This antibody is purified using Protein G, to obtain a total IgG fraction - Background
-
Background: Factor VIIa (FVIIa) is a key serine protease involved in the initiation of the coagulation cascade. FVIIa requires tissue factor (TF), a membrane bound protein, as an essential cofactor for maximal activity towards its biological substrates Factor X, Factor IX and Factor VII (FVII). - Product Citations
-
Selected references: Lopez-Vilchez et al. (2009). Traffic of rFVIIa through Endothelial Cells and Redistribution into Subendothelium: Implications for a Prolonged Hemostatic Effect. Journal of Coagulation Disorders, October 1: (1). (immunolocalization) -